The latest price target for SpringWorks Therapeutics (NASDAQ:SWTX) was reported by JP Morgan on September 4, 2024. The analyst firm set a price target for $68.00 expecting SWTX to rise to within 12 months (a possible 69.49% upside). 15 analyst firms have reported ratings in the last year.

The latest analyst rating for SpringWorks Therapeutics (NASDAQ:SWTX) was provided by JP Morgan, and SpringWorks Therapeutics maintained their overweight rating.

There is no last upgrade for SpringWorks Therapeutics

There is no last downgrade for SpringWorks Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of SpringWorks Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for SpringWorks Therapeutics was filed on September 4, 2024 so you should expect the next rating to be made available sometime around September 4, 2025.

While ratings are subjective and will change, the latest SpringWorks Therapeutics (SWTX) rating was a maintained with a price target of $64.00 to $68.00. The current price SpringWorks Therapeutics (SWTX) is trading at is $40.12, which is out of the analyst’s predicted range.